Asset

BRODALUMAB

Amgen Inc. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (2)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT01199289phase2completed2010-10-042011-12-21AmgenA Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma
NCT01059448phase2terminated2010-06-032011-04-05AmgenSafety and Efficacy of AMG 827 in Subjects With RA

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)